Tenpoint Therapeutics Raises $235 Million to Advance Commercialization of YUVEZZI, the First and Only FDA-Approved Dual-Action Eye Drop for Presbyopia

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Please feel free to point out in the comments. This article is only an introduction to drugs related to medical health.Non-therapeutic program recommendations (if applicable); This article does not constitute any investment advice.。

PharmaCircleMonitoring shows:Recently,Tenpoint Therapeutics Limited announced that it has successfully raised funds through the completion of a Series B preferred stock financing and a credit financing arrangement.$235 millionFunds.

The scale of this Series B equity financing is$85 million, byJanus Henderson, EQT Nexus, an affiliate fund of殷拓集团,Hillhouse Capital(Hillhouse) and British Business Bank jointly led the investment.

Existing investors participating in this round of financing include EQT Life Sciences, Sofinnova Partners, F-Prime, and Eight Roads.Qiming Venture PartnersQiming Venture Partners USA, AdBio, and Wille.

In addition to the Series B equity financing, Tenpoint Therapeutics has also reached an agreement with Hercules Capital to obtain$150 millionThe undiluted priority secured term loan facility.

Tenpoint Therapeutics CEO Henric Bjarke said, "We are deeply grateful for the strong support from a powerful consortium of global long-term investors. This financing round fully reflects the investors' recognition of YUVEZZI. This novel therapy, with its differentiated advantages, will offer a new option for millions of patients suffering from presbyopia and whose daily lives are restricted." He also mentioned, "With the further strengthening of the company’s balance sheet after this financing, we plan to officially launch the YUVEZZI product in the second quarter."

David Guyer, MD, Chairman of Tenpoint Therapeutics, noted: "The successful completion of the Series B financing coinciding with the approval of YUVEZZI presents a highly valuable opportunity. It establishes an ideal foundation for this top-tier ophthalmology team to go public and launch this first-class combination drug into a vast market."

Dr. Agustin Mohedas, Portfolio Manager and Research Analyst at Janus Henderson Investors, commented: "YUVEZZI has unique and favorable safety and tolerability profiles. As Tenpoint Therapeutics advances its product to market, we are increasingly confident in its commercial potential to gain broad recognition from patients and healthcare professionals. The management team at Tenpoint has deep experience in the ophthalmology field, successfully achieving key milestones in the commercialization process, and possesses the core capability to bring this differentiated innovative therapy to the presbyopia treatment market."

About Tenpoint Therapeutics

Tenpoint Therapeutics, Ltd. is a global biotechnology enterprise with a core focus on advancingYUVEZZI™ (Carbachol & Brimonidine Tartrate Ophthalmic Solution, Concentration Specification 2.75%/0.1%)Commercialization and implementation. This product is the world's first and currently the only compound eye drop used for the treatment of presbyopia. Presbyopia, an eye condition, affects nearly128 millionPopulation, the scale of the affected population worldwide is approximately2 BillionTenpoint Therapeutics, based on clinical needs, deeply collaborates with ophthalmology professionals to provide innovative treatment solutions for age-related eye conditions.

References:

PharmaCircle Data;

Moxie Pharma pharma.bcpmdata.com (formerly Pharma Data Cloud);

https://news.bloombergtax.com；

tenpointtherapeutics.com；

https://www.businesswire.com/news/home/20260128574430/en/Tenpoint-Therapeutics-Secures-%24235-Million-through-Series-B-Stock-Financing-and-Credit-Facility-to-Accelerate-Commercialization-of-YUVEZZI；

; etc.